Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGEX-VASC1
- Development stage
- Discontinued
- Lead developer
- Serina Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
AGEX-VASC1 is a preclinical-stage cell therapy candidate developed by AgeX Therapeutics for the treatment of tissue ischemia, including cardiac ischemia. It is a stem cell-derived therapeutic designed to provide vascular support and promote the regeneration of damaged tissues. The program is part of AgeX's regenerative medicine pipeline, which utilizes technologies related to cell immortality and telomerase biology. The development of AGEX-VASC1 has been supported by strategic investments and credit facilities from Juvenescence Limited. Following a 2023 merger, AgeX Therapeutics became part of a combined entity with Serina Therapeutics.
Beyond the preview
Go deeper on AGEX-VASC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGEX-VASC1.